View in EDS

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.

Saved in:
Bibliographic Details
Title: Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.
Authors: Cline EN; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA. Electronic address: ecline@acumenpharm.com., Antwi-Berko D; Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Amsterdam, the Netherlands., Sundell K; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA., Johnson E; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA., Hyland M; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA., Zhang H; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA., Vanderstichele H; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA., Kaplow J; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA., Dean RA; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA., Stoops E; ADx NeuroSciences, Technologiepark 6, Gent, Belgium., Vanmechelen E; ADx NeuroSciences, Technologiepark 6, Gent, Belgium., Koel-Simmelink MJA; Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Amsterdam, the Netherlands., Teunissen CE; Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Amsterdam, the Netherlands., Sethuraman G; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA., Feaster T; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA., Siemers E; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA., Jerecic J; Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA.
Source: The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2025 Apr; Vol. 12 (4), pp. 100082. Date of Electronic Publication: 2025 Feb 17.
Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101638820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2426-0266
DOI:10.1016/j.tjpad.2025.100082